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Purpose: To determine the proinflammatory cytokine profile of aqueous humor from glaucomatous eyes.
Methods: Aqueous humor samples were prospectively collected from 38 eyes (26 primary open angle glaucoma [POAG]
and 12 primary angle closure glaucoma [PACG] eyes) of 37 medically treated glaucoma patients and 23 cataract subjects
recruited in an institutional setting in this case-controlled study. The main outcome measure was to quantify the levels of
29 inflammatory cytokines in the aqueous of glaucoma and cataract subjects using a multiplexed cytokine analysis. Data
on patient demographics, duration of glaucoma, preoperative intraocular pressure (IOP) as well as duration of anti-
glaucoma therapy were also collected for correlation analysis.
Results: Mean duration of glaucoma was 53.8 months (range 1–360 months). Aqueous obtained from the glaucoma
patients showed increased concentration of interleukin (IL)-9 (p=0.032), IL-12 (p=0.003), interferon (IFN)-α (p=0.034),
IFN-γ (p=0.002), monokine induced by interferon-gamma (MIG or CXCL9) (p=0.006), and IL-10 (p=0.050), compared
to the cataract group. The POAG group had higher IL-12 (p=0.011), IFN-γ (p=0.005), and CXCL9 (p=0.047) levels than
controls, while the PACG group had higher interleukin-8 (CXCL8) (p=0.015) and CXCL9 (p=0.023) levels than the
controls. No significant correlation was observed between aqueous cytokine level and preoperative IOP and duration of
glaucoma. Duration of topical Timolol and Alphagan therapy correlated negatively with CXCL8 (r=-0.588, p=0.035),
respectively.
Conclusions: Primary glaucoma is associated with an aqueous inflammatory response and this is different between POAG
and PACG groups. Duration of glaucoma treatment may have an effect on cytokine profile in the aqueous.
Glaucoma is characterized by the presence of a typical
glaucomatous optic neuropathy with a corresponding visual
field  defect  and  is  usually  associated  with  an  elevated
intraocular pressure (IOP), which is a known risk factor for
disease  progression  [1,2].  In  glaucoma,  aqueous  humor
drainage through the trabecular meshwork largely determines
the IOP and an elevated IOP is a result of trabecular meshwork
resistance  to  aqueous  outflow.  The  aqueous  humor  is
important for the maintenance of both physiologic function
and metabolic homeostasis of intraocular structures within the
anterior  chamber  such  as  the  trabecular  meshwork,  iris,
corneal endothelium, and lens [3].
Altered  cytokine  and  chemokine  composition  of  the
aqueous humor has been observed in various ocular disease
conditions including uveitis, diabetic retinopathy and age-
related macular degeneration [4,5]. Increased concentrations
of tumor necrosis factor (TNF)-α [6], transforming growth
factor  (TGF)-β2  [7-9],  vascular  endothelial  growth  factor
(VEGF)  [10],  interleukin  (IL)-6  [11,12],and  interleukin-8
Correspondence to: Jing Li, Ph.D., Xin Hua Hospital, Shanghai Jiao
Tong  Univeristy  School  of  Medicine,  Shanghai,  China;  Phone:
86-25078843; FAX: 86-25078500; email: li.jing@seri.com.sg
(CXCL8)  [11,13]  have  been  observed  in  glaucomatous
aqueous humor. The significance and role in which these
aqueous cytokines may play in the pathogenesis of primary
glaucoma is still unclear. Age-related accumulation of oxygen
free radicals can lead to the induction of oxidative stress
related trabecular cell death as well as the upregulation of
several  inflammatory  cytokines  such  as  TGF-β2,  IL-1,
IL-6,and CXCL8 [14,15]. Other cytokines have also been
proposed to contribute to changes in expression levels of
matrix  metalloproteinase  (MMP)  and  tissue  inhibitors  of
metalloproteinase (TIMP) [16] in the trabecular meshwork
resulting in an alteration in extra-cellular matrix production
that can give rise to an increase in aqueous outflow resistance.
To  date,  the  profile  of  aqueous  cytokines  in  the  two
primary glaucoma subgroups is still not fully described. This
study reports the concentrations of 29 aqueous cytokines in
patients  with  primary  open  angle  glaucoma  (POAG)  and
primary  angle  closure  glaucoma  (PACG)  in  an  Asian
population.  Correlations  of  elevated  aqueous  cytokines  to
demographic and clinical factors are also reported.
METHODS
Patient eligibility and recruitment: This study was approved
prospectively by the local Institutional Review Board (IRB)
Molecular Vision 2012; 18:431-438 <http://www.molvis.org/molvis/v18/a46>
Received 26 October 2011 | Accepted 8 February 2012 | Published 11 February 2012
© 2012 Molecular Vision
431at  the  Singapore  National  Eye  Centre  and  performed  in
accordance to the tenets of the Declaration of Helsinki. Thirty-
seven glaucoma patients on topical medication and 23 non-
glaucomatous cataract patients with cataract and no previous
history of any topical medical therapy were recruited from the
glaucoma  subspecialty  clinic  and  general  comprehensive
clinic respectively at the Singapore National Eye Centre. Any
patient with a known systemic inflammatory, autoimmune or
immunosuppressive disease as well as a pre-existing ocular
disease  (retinal  vein  occlusion,  retinal  artery  occlusion,
diabetic  retinopathy,  age-related  macular  degeneration)  or
previous  ocular  surgery  was  excluded  from  the  study.
Informed written consent with regard to donation and storage
of human fluid samples was obtained from all patients.
Of the 38 eyes of 37 glaucoma patients, 26 had a diagnosis
of primary open angle glaucoma (POAG) and 12 with primary
angle closure glaucoma (PACG). The diagnosis of primary
glaucoma  and  its  subtypes  was  based  on  the  IOP,
glaucomatous  nerve  damage  (defined  by  the  presence  of
neuro-retinal rim loss of the optic nerve head with a vertical
cup-disc ratio of 0.7 or more) with corresponding visual field
loss, presence of occludable angles on indentation gonioscopy
(PACG  is  diagnosed  when  the  pigmented  trabecular
meshwork was not visualized in at least 2 quadrants with or
without peripheral anterior synechiae) and the absence of
features suggestive of a secondary etiology. Only 1 of 12
PACG eyes had a prior history of acute angle closure. Laser
peripheral iridotomy was performed in all PACG eyes upon
diagnosis, followed by a topical steroid therapy for a period
of 2 weeks. Trabeculectomy with mitomycin C was performed
in  glaucomatous  eyes  with  sub-optimally  medically
controlled IOP as well as progressive visual field loss and
optic disc cupping; and in the presence of a visually significant
cataract, a combined phacotrabeculectomy surgery was then
performed. Prior to surgery, 34 glaucoma eyes were treated
with  a  beta-blocker  Timolol  0.5%  (Timoptic;  Merck,
Whitehouse Station, NJ), 28 eyes with a prostaglandin analog
(PGA;  Travoprost:  Travatan,  Alcon,  Fort  Worth,  TX;
Latanoprost; Xalatan; Pfizer, New York, NY; Bimatoprost;
Lumigan; Allergan Inc., Irvine, CA), 12 eyes with an alpha-
agonist Brimonidine (Alphagan; Allergan Inc.) and 8 eyes
with  a  carbonic  anhydrase  inhibitor  (CAI;  Brinzolamide:
Azopt; Alcon; Dorzolamide: Trusopt; Merck). Six eyes were
on monotherapy while the rest were on at least 2 eye drops.
Routine  phacoemulsification  surgery  with  intraocular  lens
implant was performed for all 23 non-glaucomatous eyes with
visually significant cataract.
Aqueous  collection:  Aqueous  humor  collection  was
performed under sterile conditions before commencement of
surgery for all patients. In all PACG eyes, aqueous samples
were collected at least 1 month after laser peripheral iridotomy
procedure. In the only eye with a previous acute angle closure,
aqueous was collected one month after the acute attack has
resolved. One-hundred micro liters (100 μl) of aqueous humor
was  withdrawn  using  a  30-gauge  needle  on  a  tuberculin
syringe via an anterior chamber paracentesis. Aqueous sample
was frozen at −80 °C within 2 h of collection till further
analysis.
Cytokine  analysis:  Bio-Plex  ProTM  magnetic  color-bead-
based multiplex assay (Bio-Rad Laboratories, Inc., Hercules,
CA) was used to measure the concentrations of the following
human cytokines/chemokines: IL-1Ra (Interleukin-1 receptor
antagonist), IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10,
IL-12,  IL-13,  IL-15,  IL-17,  G-CSF  (granulocyte  colony-
stimulating  factor),  GM-CSF  (granulocyte-  macrophage
colony-stimulating factor), IFN-γ (interferon-gamma), CCL2
(MCP-1, monocyte chemotactic protein-1), CCL3 (MIP-1α,
macrophage inflammatory protein-1-alpha), CCL4 (MIP-1β,
macrophage inflammatory protein-1-beta), CCL5 (RANTES,
Regulated upon Activation, Normal T-cell Expressed, and
Secreted), CCL11 (Eotaxin, eosinophil chemotactic protein),
CXCL8  (IL-8),  CXCL9  (MIG,  monokine  induced  by
interferon-gamma),  CXCL10  (IP-10,  interferon-gamma-
induced protein 10), TNF-α (tumor necrosis factor-alpha),
IFN-α (interferon-alpha), PDGF-BB (platelet-derived growth
factor-BB), basic-FGF (basic fibroblast growth factor) and
VEGF (vascular endothelial growth factor). The assay was
conducted  according  to  the  manufacturer’s  instruction.
Thirty-five micro liters (35 μl) of aqueous humor sample was
used in each reaction. Fluorescence intensity (FI) from the
immunoassay  was  acquired  and  analyzed  using  Bio-Plex
Manager 6.0. Concentrations that were lower than the low
limit of detection (LOD) was defined as non-measurable.
Classification analysis: Step-wise analysis was performed to
generate cytokine profiles to best separate glaucoma aqueous
samples from cataract samples and to separate POAG from
PACG. For each cytokine, the measured concentration was
logarithmically transformed. An initial analysis was used on
all available cytokines, which generated a poor separation
between  groups.  The  analysis  was  then  refined,  by  using
cytokines and chemokines that showed significant differences
between the compared groups by two-sample Student’s t-test
(p-value  ≤0.05).  The  panel  of  differentially  expressed
cytokines was then further reduced by the removal of highly
correlated cytokines. The accuracy of the heat map separation
for each group was calculated as follow: the number of true
subjects (based on clinical diagnosis) divided by the number
of total subjects within the group and the result multiplied by
100%. A separate decision tree analysis was performed to
select step-wise marker cytokines using WEKA, a machine
learning algorithms for data mining tasks. A fivefold cross
validation was conducted to examine the error rate of this
method.
Statistical analysis: Statistical analysis was performed using
Predictive Analytics Soft Ware (PASW) Statistics 18 (IBM
Corporation,  Armonk,  NY).  Statistical  significance  was
accepted at p≤0.05. For categorical variables, the frequency
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Pearson χ2 analysis. For numerical variables in parametric
distribution, the one-way ANOVA analysis was performed.
For  differences  in  cytokine  concentrations,  the  Mann–
Whitney U test with Bonferroni correction was performed and
the  resulting  p-values  were  reported.  For  comparisons
involving  the  PACG  group,  a  multivariate  binary  logistic
regression  analysis  was  also  performed,  to  adjust  for  the
differences in axial length and the resulting p-values were
reported. The two-tailed, nonparametric Spearman method
was used to assess for correlations between variables.
RESULTS
Patient demographics: Mean age of the glaucoma group was
69.9 years (range 58.7–84.4) and that of the cataract group
was 66.5 years (range 26.6–88.8; p=0.228) as shown in Table
1. The mean duration of glaucoma from diagnosis was 53.8
months  (range  1–360  months).  Phacotrabeculectomy  and
trabeculectomy surgery were performed for 19 and 4 eyes,
respectively.  The  remaining  15  glaucoma  eyes  underwent
phacoemulsification surgery alone. The mean axial length
measurements of both the glaucoma and cataract groups were
shown in Table 1. The PACG group had a significantly shorter
axial length when compared to both POAG (p=0.029) and
cataract  groups  (p=0.023).  No  statistically  significant
difference in axial length was observed between the POAG
and cataract groups.
Aqueous  cytokines:  The  aqueous  concentrations  of  29
cytokines in both the glaucoma and cataract groups were
measured. The aqueous cytokines were compared between
groups  in  two  aspects:  the  percentage  of  samples  with
measurable concentrations and the median concentration for
each cytokine.
IL-4, IL-5, CCL3, and G-CSF was detected in less than
50% of samples in both control and glaucoma groups and
therefore  were  not  included  in  further  analysis.  The
concentrations as well as the sensitivity of analysis for the rest
of the cytokines are shown in Table 2.
TABLE 1. DEMOGRAPHIC AND CLINICAL DATA OF GLAUCOMA AND CATARACT PATIENTS.
Characteristics Glaucoma patients Cataract non-glaucomatous
patients
p-value
Total number 37 23  
Glaucoma subgroups 25 POAG    
  12 PACG    
Age (Mean±SDa) 69.9±7.6 66.5±11.8 0.228d
Gender     0.926e
Male 17 11  
Female 20 12  
Race     0.600e
Chinese 33 19  
Malay 3 2  
Indian 1 1  
Others 0 1  
AXLb (Mean±SD) POAG: 24.2±1.8 23.8±1.6 0.026df
PACG: 23.0±0.9 0.250dg
      0.023dh
Surgery types Number of eyes Number of eyes  
Phacotrabeculectomy 19 0  
Trabeculectomy 4 0  
Phacoemulsification 15 23  
Medical Therapyc Number of eyes Number of eyes  
BB 34 0  
PGA 28 0  
AA 12 0  
CAI 8 0  
Number of drops
One 6 0  
Two or more 32 0  
aSD: Standard deviation; cAXL: axial length; cBB: beta-blocker, AA: alpha-agonist, CAI: carbonic anhydrase inhibitor, PGA:
prostaglandin analog; d2-samples independent t-test; ePearson's χ2; fbetween POAG and PACG; gbetween POAG and cataract;
hbetween PACG and cataract.
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433Compared to the cataract group, there was a significantly
higher proportion of samples with measurable concentrations
of  the  following  cytokines  in  the  glaucoma  group:  IL-2
(p=0.008), IL-6 (p=0.014), IL-10 (p=0.015), IL-12 (p=0.020),
IFN-γ (p=0.000), IFN-α (p=0.002), IL-1β (p=0.019), IL-7
(p=0.002), GM-CSF (p=0.015), IL-9 (p=0.046), and CXCL9
(p=0.003;  χ2  test).  Among  these  cytokines,  the  median
concentrations of IL-10 (p=0.050), IL-12 (p=0.003), IFN-γ
(p=0.002),  IFN-α  (p=0.034),  IL-9  (p=0.032),  and  CXCL9
(p=0.006)  were  also  significantly  higher  in  the  glaucoma
group (Figure 1).
When the glaucoma group was further separated into
POAG  and  PACG,  we  found  significantly  elevated
concentrations  of  IL-12  (p=0.011),  IFN-γ  (p=0.005),  and
CXCL9 (p=0.047) in the POAG aqueous compared to the
cataract  group.  Both  CXCL8  (p=0.015)  and  CXCL9
(p=0.023)  concentrations  were  significantly  higher  in  the
PACG group compared to the cataract group, after adjustment
for differences in axial length using binary logistic regression
analysis.
There was no significant difference in any of the cytokine
concentration between the two glaucoma subgroups, with and
without adjustments for axial length (Table 3).
Correlation analysis: There was no correlation between the
aqueous  cytokine  levels  and  clinical  parameters  such  as
preoperative  IOP  and  duration  of  glaucoma.  However,
duration of Timolol and Alphagan therapy were found to
correlate negatively with CXCL8 (r=-0.588, p=0.035, n=13),
respectively.  No  correlation  between  age  and  cytokine
concentration was found in the cataract group.
Classification  analysis:  Heat  map  analysis  identified  the
combination of IL-12 and CXCL8 as markers to separate the
glaucoma from the cataract group, with an accuracy of 84%
for the cataract and 83% for the glaucoma groups. This was
confirmed by a decision tree analysis. Based on the decision
tree  analysis,  aqueous  humor  samples  with  an  IL-12
concentration greater than 11 pg/ml or those with an IL-12
concentration  in  the  range  between  7  to  11  pg/ml  and  a
CXCL8 concentration greater than 3.3 pg/ml were categorized
as glaucomatous, while the rest were non-glaucomatous. The
accuracy of this mathematical formula in separating glaucoma
and non-glaucoma cataract samples was the same as the heat
map analysis. Using the same analysis, POAG and PACG
groups  were  separated  by  the  combination  of  IL-13  and
CXCL8  with  an  accuracy  of  71%  for  both  groups.  The
decision tree analysis predicted that aqueous humor samples
with IL-13 concentration greater than 6 pg/ml and CXCL8
TABLE 2. AQUEOUS CYTOKINE CONCENTRATIONS IN GLAUCOMA AND NON-GLAUCOMATOUS CATARACT GROUPS.
  Cataract (n=23) Glaucoma (n=38)    
Cytokines Median Range Measurable Median Range Measurable p-valuea Sensitivity
IL-2* 2.16 0–8 14/23 3.01 0–27 34/38 0.154 1.6
IFN-γ* 12.73 0–91 12/23 26.98 0–1167 36/38 0.002 6.4
IL-13 3.85 0–8 19/23 4.82 0–46 35/38 0.432 0.7
IL-17 2.27 0–11 8/23 3.98 0–241 22/38 0.227 3.3
IL-6* 2.23 0–14 9/23 4.02 0–89 27/38 0.789 2.6
IL-10* 1.45 0–5 18/23 1.91 0–64 37/38 0.050 0.3
IL-12* 7.15 0–27 17/23 14.06 0–68 36/38 0.003 3.5
IL-1β* 0.60 0–6 14/23 0.72 0–5 33/38 1.000 0.6
TNF-α* 9.58 0–34 16/23 12.65 0–82 35/38 0.086 6.0
IL-1Ra 8.58 3–96 10/17 8.74 0–84 14/34 1.000 5.5
IL-15 8.50 6–29 17/17 9.00 0–26 33/34 1.000 2.4
IFN-α* 26.24 0–139 16/22 37.90 0–311 37/38 0.034 4.3
CCL2 180.89 32–962 23/23 295.22 0–1072 37/38 0.086 1.1
CCL4 16.94 4–137 23/23 33.06 1–229 37/38 0.056 2.4
CCL5 6.30 0–25 16/17 6.30 0–39 33/34 1.000 1.8
CCL11 4.90 0–10 12/17 5.50 0–17 29/34 1.000 2.5
CXCL8 3.08 1–20 22/23 5.58 0–81 36/38 0.060 1.0
CXCL9* 62.20 0–3603 18/20 214.97 21–1351 38/38 0.006 1.2
CXCL10 56.27 0–5038 20/22 147.93 0–4677 37/38 0.290 6.1
IL-7* 1.09 0–15 10/23 1.92 0–4 31/38 0.728 1.1
IL-9* 5.50 0–11 15/17 7.57 0–17 33/34 0.032 2.5
GM-CSF* 135.45 0–766 18/23 164.05 0–6815 37/38 0.301 2.2
PDGF-BB 3.11 0–14 11/17 2.26 0–9 27/34 1.000 2.9
Basic-FGF 10.62 7–44 17/17 11.39 0–35 33/34 1.000 1.9
VEGF 43.73 22–124 17/17 54.35 0–151 33/34 1.000 3.1
The aqueous concentrations of IFN-γ, IL-10, IL-12, IFN-α, CXCL9 and IL-9 were significantly elevated in the glaucoma group
compared to the cataract group (significant p-values are highlighted in bold). a p-values were obtained from Mann–Whitney U
test with Bonferroni correction. *p<0.05 for the comparison of the percentage of measurable samples between glaucoma and
cataract groups using Pearson’s χ2 analysis. All concentrations of cytokines are in pg/ml.
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434Figure 1. Scatter plots showing distribution level of IL-10, IL-12, IFN-γ, IFN-α, CXCL8, CXCL-9, and IL-9 in aqueous humor from POAG
(circles), PACG (squares) and cataract controls (triangles). A Mann–Whitney U test with Bonferroni correction was performed between groups
and a significant difference was accepted at p≤0.05. The solid lines indicate median concentrations. Median concentrations of IL-10 (p=0.050),
IL-12 (p=0.003), IFN-γ (p=0.002), IFN-α (p=0.034), IL-9 (p=0.032), and CXCL9 (p=0.006) were significantly higher in the glaucoma group
compared to the cataract controls. Significantly elevated concentrations of IL-12 (p=0.011), IFN-γ (p=0.005), and CXCL9 (p=0.047) was
observed in the POAG aqueous, while CXCL8 (p=0.015) and CXCL9 (p=0.023) concentrations were significantly higher in the PACG group,
compared to the cataract group.
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435concentration greater than 8.5 were PACG eyes. In addition,
aqueous humor samples with CXCL8 concentration in the
range between 4.3 and 8.4 pg/ml and IL-13 concentration less
than 4.5 pg/ml were also that from PACG eyes. The accuracy
of this mathematical formula in separating PACG and POAG
eyes was 71% and 92%, respectively.
DISCUSSION
This study revealed significant differences in the aqueous
cytokine  profile  of  glaucomatous  eyes  compared  to  age-
matched  non-glaucomatous  cataract  eyes.  A  total  of  6
cytokines  were  found  significantly  elevated  in  glaucoma
samples compared to controls, which include IL-10, IL-12,
IFN-γ, IFN-α, IL-9, and CXCL-9. The POAG aqueous had a
significant  increase  in  IFN-γ,  IL-12,  and  CXCL9
concentrations, thus suggesting a Th1-type proinflammatory
response, while the PACG aqueous only had elevated levels
of  CXCL-8  and  CXCL-9  when  compared  to  the  cataract
controls. The heat map and decision tree analysis showed that
both  IL-12  and  CXCL8  were  signature  cytokines  for
differentiating the glaucoma group from the controls and this
was consistent with the univariate analysis. To the best of our
knowledge, this study is the first comprehensive evaluation of
an  extensive  array  of  cytokines  in  the  aqueous  humor  of
glaucomatous eyes, both overall as well as between the PACG
and POAG subgroups in an Asian population.
Previous  studies  have  reported  elevated  aqueous
concentrations of IL-6 [11,12], TNF-α [6], CXCL8 [11,13],
and VEGF [10,17] in glaucomatous eyes. The concentrations
of  these  cytokines  were  also  found  to  be  higher  in  the
glaucoma  group  compared  to  the  controls  in  our  study.
However  these  differences  were  not  significant  after
application  of  the  Bonferroni  correction.  Our  study  also
showed  a  significantly  higher  proportion  of  glaucoma
aqueous with a measurable concentration of IL-6 cytokine.
We believe that these changes in aqueous cytokines are related
to glaucoma and the discrepancies observed in various studies
are largely due the sample size and variation within each
group.  Interestingly,  in  those  patients  who  had  received
Alphagan (n=12) and Timolol therapy (n=38), we found a
significant  negative  correlation  between  the  duration  of
therapy and CXCL8 concentration, thus suggesting that long-
term anti-glaucoma treatment may have an effect on aqueous
cytokine composition.
The differences in cytokines between glaucomatous and
non-glaucomatous  aqueous  suggest  possible  complex
changes  associated  with  the  glaucoma  disease  process.
Increased  levels  of  IL-10,  IL-12,  and  IFN-α  are  likely
TABLE 3. AQUEOUS CYTOKINE CONCENTRATIONS IN PACG AND POAG GROUPS.
  POAG (n=26) PACG (n=12)  
Cytokines Median Range Measurable Median Range Measurable Sensitivity
IL-2 3.12 0–27 24/26 2.84 0–5 10/12 1.6
IFN-γ 26.98* 0–1167 24/26 27.62 13–369 12/12 6.4
IL-13 4.24 0–13 23/26 6.39 3–46 12/12 0.7
IL-17 4.15 0–151 16/26 3.30 1–241 6/12 3.3
IL-6 2.85 0–28 16/26 4.70 2–89 11/12 2.6
IL-10 1.87 0–11 25/26 2.10 1–64 12/12 0.3
IL-12 12.42* 0–68 25/26 15.90 0–32 11/12 3.5
IL-1β 0.72 0–5 23/26 0.72 0–2 10/12 0.6
TNF-α 12.14 0–59 24/26 13.17 5–82 11/12 6.0
IL-1Ra 8.58 0–52 18/24 14.25 3–84 9/10 5.5
IL-15 8.37 0–26 23/24 9.63 5–18 10/10 2.4
IFN-α 35.10 0–311 25/26 38.25 31–128 12/12 4.3
CCL2 287.14 0–615 25/26 325.61 145–1072 12/12 1.1
CCL4 31.84 1–111 25/26 36.88 12–229 12/12 2.4
CCL5 6.30 0–39 23/24 5.52 5–20 10/10 1.8
CCL11 5.30 0–17 20/24 5.89 0–10 9/10 2.5
CXCL8 4.88 0–42 24/26 8.00† 3–81 12/12 1.0
CXCL9 183.43* 21–1015 26/26 281.61† 73–1351 12/12 1.2
CXCL10 116.80 0–2311 25/26 177.39 31–4677 12/12 6.1
IL-7 1.88 0–3 23/26 2.06 0–4 8/12 1.1
IL-9 7.11 0–17 23/24 8.09 5–15 10/10 2.5
GM-CSF 151.38 0–3139 25/26 185.12 121–6815 12/12 2.2
PDGF-BB 2.10 0–9 9/24 2.69 1–6 5/10 2.9
Basic-FGF 11.39 0–34 23/24 12.16 9–35 10/10 1.9
VEGF 51.44 0–87 23/24 69.6950 27–151 10/10 3.1
*p<0.05, between POAG and cataract; †p<0.05, between PACG and cataract. p-values were obtained from Mann–Whitney U
with Bonferroni correction. All concentrations of cytokines are in pg/ml.
Molecular Vision 2012; 18:431-438 <http://www.molvis.org/molvis/v18/a46> © 2012 Molecular Vision
436associated with activation of leukocytes such as monocytes,
macrophages and dendritic cells, in glaucomatous eyes. IL-12
is a key cytokine that links the innate immune response to a
Th1 dominant adaptive immune response, by stimulating IFN-
γ production from T cells and natural killer cells. CXCL9 is
also  known  to  stimulate  Th1  type  immune  responses  by
inducing the recruitment of activated Th1 cells [18,19]. A
positive  correlation  was  found  between  IL-12  and  IFN-γ
levels  in  our  study  (r=0.356,  p=0.028).  The  Th1  type
inflammatory response was evident in the POAG aqueous.
However, PACG aqueous showed a less proinflammatory
cytokine profile compared to POAG, with only CXCL8 and
CXCL9  levels  were  significantly  higher  than  cataract
controls.
IL-9 was found significantly increased in glaucomatous
aqueous compared to controls, although this difference was
not  observed  when  the  glaucoma  groups  was  analyzed
separately as POAG and PACG subgroups. This was most
likely due to a reduced sample size. IL-9 was measured in
almost  all  glaucomatous  and  non-glaucomatous  aqueous
samples  tested,  thus  indicating  that  it  is  an  important
component of the aqueous immune milieu. Originally linked
to Th2 cells, IL-9 is expressed by a specific subset of T cells
called Th9 cells [20]. Although the main target of IL-9 is the
mast cell, it also stimulates the expansion of Th17 and Treg
cells [20]. Elevated IL-9 concentration was also observed in
idiopathic  uveitic  aqueous  (unpublished  data).  However,
IL-17 level was not significantly elevated in either POAG or
PACG groups compared to cataract. The significance of IL-9
in both glaucomatous and non-glaucomatous aqueous remains
unknown.
In a study involving the simultaneous analysis of multiple
factors from each sample, several factors such as sample size
and method of data analysis, can affect the outcome. The
Bonferroni correction was applied in this study to determine
the  significance  of  changes  in  cytokine  levels.  This  is  a
conservative statistical adjustment used for the verification of
data  observations  but  it  may  mask  potential  changes  in
exploratory studies. In fact, more cytokines were found to be
significantly  increased  in  both  POAG  and  PACG  groups
compared to controls when the Mann–Whitney U test was
performed without Bonferroni correction and these included
IL-6, TNF-α, VEGF, and CXCL8 as discussed above. Due to
the  complicated  intrinsic  dependence  of  cytokines,  binary
logistic  multivariate  analysis  was  not  able  to  identify
cytokines which could be primarily associated with each type
of glaucoma. The classification analysis was employed to
compliment the data analysis. Although the present study tried
to present data in a conservative way, further studies with a
larger sample size would be needed to obtain a confirmative
aqueous  cytokine  profile  in  both  glaucoma  and  cataract
groups.
Furthermore, other parameters such as axial length of the
eye,  age  and  gender,  may  also  affect  the  cytokine  data
measured  [21].  There  was  no  statistically  significant
difference in age and gender distribution among the study
groups in this study. However, we observed a significantly
shorter axial length in the PACG group compared to both
POAG  and  cataract  groups.  Multivariate  analysis  was
performed  taking  these  factors  into  consideration  and  the
outcome  was  largely  the  same  as  per  univariate  analysis.
Similarly, we did not find any significant correlation between
cytokine  concentrations  and  age  and  axial  length  in  the
cataract group.
Lastly,  both  systemic  and  topical  medications  may
influence the aqueous immune milieu and they include alpha-
agonist  prostatic  medications  and  topical  anti-glaucoma
medications. We were unable to account for the effect of the
former therapy as this information was not obtained during
the study. Chronic use of topical anti-glaucoma medications
is associated with conjunctival and aqueous inflammation
[22-24],  with  the  latter  shown  to  be  associated  with
medications  such  as  prostaglandin  analogs  and  alpha-
agonists. Topical prostaglandin analogs are commonly used
for IOP control and the majority of these eyes were on at least
1 topical medication. As such, this could be a confounder in
the interpretation of our results and ideally, aqueous samples
obtained  from  newly  diagnosed  glaucoma  patients  before
commencement of medical therapy would help determine the
significance and role of chronic anti-glaucoma medication on
the detection of aqueous inflammation. However, this is not
without ethical implications.
In conclusion, the present study showed that primary
glaucoma is associated with changes in the aqueous cytokine
profile. POAG is different to PACG, with a Th1 type response
being observed in the former group, while the latter group had
a  milder  inflammatory  response.  Further  studies  will  be
necessary to determine the significance in the differential
inflammatory  protein  expression  found  between  the  two
primary  glaucoma  subgroups  as  well  as  to  identify  the
inflammatory protein molecules which may play a role in
post-operative wound healing response following filtration
surgery.
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